Stay updated on Pembrolizumab Combo in Metastatic Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Metastatic Lung Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Metastatic Lung Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe KEYNOTE-189 record for pembrolizumab with pemetrexed/platinum chemotherapy versus chemotherapy alone is displayed, including its study details, eligibility criteria, outcome measures, posted results, and linked study documents.SummaryDifference71%

- Check18 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs.SummaryDifference1%

- Check31 days agoChange DetectedThe ClinicalTrials.gov footer now identifies the site revision as v3.7.2 instead of v3.7.1.SummaryDifference0.2%

- Check38 days agoChange DetectedThe footer’s site revision number changed from v3.7.0 to v3.7.1 while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check59 days agoChange DetectedThe page now shows a 403 Forbidden error indicating restricted access to the study record. Additionally, sponsor-related content and study documents associated with Merck were removed from the page.SummaryDifference22%

Stay in the know with updates to Pembrolizumab Combo in Metastatic Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Metastatic Lung Cancer Clinical Trial page.